Prime Medicine CEO Gottesdiener resigns; Reine named CEO; positive CGD data; restructures to liver focus

Prime Medicine, Inc.

Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.
Jeff Marrazzo named Executive Chair of the board.
First clinical data for PM359 in CGD: 58% DHR positivity at Day15, 66% at Day30, well above 20% threshold; rapid engraftment.
Company to deprioritize CGD programs, seek partner for PM359; focus on Wilson's Disease and AATD with IND/CTA in 1H2026 and mid-2026.
Workforce reduction and cost cutting to reduce cash needs; Beam arbitration ongoing.

item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Allan Reine

member of the Board of Directors

PRME · Prime Medicine, Inc.

Effective: 2025-05-19
Filed: May 19, 2025, 7:59 PM ET

The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director

Departed

Keith Gottesdiener

President, Chief Executive Officer and principal executive officer

PRME · Prime Medicine, Inc.

Effective: 2025-05-18
Successor: Allan Reine
Filed: May 19, 2025, 7:59 PM ET

Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company

Appointed

Allan Reine

Chief Executive Officer and principal executive officer

PRME · Prime Medicine, Inc.

Effective: 2025-05-19
Filed: May 19, 2025, 7:59 PM ET

the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Allan Reine was appointed as member of the Board of Directors at Prime Medicine, Inc..

Action: appointed
Role: member of the Board of Directors

Exact text from the filing

The Board also appointed Dr. Reine to serve as a member of the Board as a Class II director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Keith Gottesdiener resigned as President, Chief Executive Officer and principal executive officer at Prime Medicine, Inc..

Action: resigned
Role: President, Chief Executive Officer and principal executive officer

Exact text from the filing

Keith Gottesdiener, M.D. had resigned as President, Chief Executive Officer and principal executive officer of the Company, and as a member of the Board of Directors of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Allan Reine was appointed as Chief Executive Officer and principal executive officer at Prime Medicine, Inc..

Action: appointed
Role: Chief Executive Officer and principal executive officer

Exact text from the filing

the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal financial officer, as Chief Executive Officer and principal executive officer of the Company

View on SEC.gov

Prime Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-122156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.